VR Adviser, LLC
- SEC CIK
- 0001615982
- Latest filing
- Aug 14, 2026
Holdings in Q3 2022
Holdings as of Sep 30, 2022, filed May 15, 2023. Long positions only; changes compare share counts with Q2 2022.
- Positions
- 31
- +4 vs. Q2 2022
- Portfolio value
- $648.1M
- +$140.3M (+27.6%) vs. Q2 2022
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| CLDXCelldex Therapeutics, Inc. | COM NEW | 75,000 | $2.11M | 0.3% | −790,116−91.3% | Reduced | History |
| Affimed N VN01045108 | COM | 1,428,571 | $2.94M | 0.5% | 00.0% | Unchanged | – |
| RLYBRallybio Corp | COM | 268,532 | $3.89M | 0.6% | 00.0% | Unchanged | History |
| ATYRaTYR PHARMA INC | COM NEW | 1,398,889 | $4.20M | 0.6% | 00.0% | Unchanged | History |
| IMCRImmunocore Holdings plc | ADS | 94,605 | $4.44M | 0.7% | +94,605 | New | History |
| LYRALyra Therapeutics, Inc. | COM | 924,170 | $4.63M | 0.7% | 00.0% | Unchanged | History |
| TRVITrevi Therapeutics, Inc. | COM | 3,050,022 | $4.70M | 0.7% | 00.0% | Unchanged | History |
| ALTAltimmune, Inc. | COM NEW | 369,306 | $4.72M | 0.7% | 00.0% | Unchanged | History |
| PRVBProvention Bio, Inc. | COM | 1,118,653 | $5.03M | 0.8% | 00.0% | Unchanged | History |
| SVRASavara Inc | COM | 4,555,038 | $7.06M | 1.1% | +437,508+10.6% | Added | History |
| RXDXPrometheus Biosciences, Inc. | COM | 121,663 | $7.18M | 1.1% | +121,663 | New | History |
| VTYXVentyx Biosciences, Inc. | COM | 207,925 | $7.26M | 1.1% | +207,925 | New | History |
| INZYInozyme Pharma, Inc. | COM | 2,709,987 | $7.26M | 1.1% | 00.0% | Unchanged | History |
| FULCFulcrum Therapeutics, Inc. | COM | 1,200,000 | $9.71M | 1.5% | +1,200,000 | New | History |
| LIANYLianBio | SPONSORED ADS | 5,378,341 | $10.8M | 1.7% | 00.0% | Unchanged | History |
| JBIOJade Biosciences, Inc. | COM | 833,927 | $13.8M | 2.1% | +243,519+41.2% | Added | History |
| DICEDICE Therapeutics, Inc. | COM | 764,979 | $15.5M | 2.4% | +764,979 | New | History |
| AKUSAkouos, Inc. | COM | 2,800,566 | $18.9M | 2.9% | +133,447+5.0% | Added | History |
| TILInstil Bio, Inc. | COM | 4,105,779 | $19.9M | 3.1% | −1,891,878−31.5% | Reduced | History |
| ANNXAnnexon, Inc. | COM | 3,220,050 | $19.9M | 3.1% | +1,291,573+67.0% | Added | History |
| GOSSGossamer Bio, Inc. | COM | 1,747,000 | $20.9M | 3.2% | +1,747,000 | New | History |
| MRNSMarinus Pharmaceuticals, Inc. | COM NEW | 3,156,803 | $21.0M | 3.2% | 00.0% | Unchanged | History |
| TERNTerns Pharmaceuticals, Inc. | COM | 3,707,891 | $21.8M | 3.4% | +3,707,891 | New | History |
| MISTMilestone Pharmaceuticals Inc. | COM | 2,425,737 | $22.3M | 3.4% | +2,425,737 | New | History |
| PLRXPliant Therapeutics, Inc. | COM | 1,080,000 | $22.6M | 3.5% | +1,080,000 | New | History |
| GHRSGH Research PLC | ORDINARY SHARES | 3,333,154 | $38.7M | 6.0% | +147,581+4.6% | Added | History |
| VRDNViridian Therapeutics, Inc. | COM | 2,130,308 | $43.7M | 6.7% | +277,389+15.0% | Added | History |
| RLMDRelmada Therapeutics, Inc. | COM | 1,518,056 | $56.2M | 8.7% | −752,016−33.1% | Reduced | History |
| COGTCogent Biosciences, Inc. | COM | 4,038,117 | $60.2M | 9.3% | 00.0% | Unchanged | History |
| ACRSAclaris Therapeutics, Inc. | COM | 4,563,962 | $71.8M | 11.1% | 00.0% | Unchanged | History |
| TCDATricida, Inc. | COM | 9,050,064 | $94.8M | 14.6% | +1,917,985+26.9% | Added | History |
Sold out since Q2 2022 (5)
Positions held at the end of Q2 2022 that are gone from this filing.
| Security | Class | Shares in Q2 2022 | Value in Q2 2022 | % of portfolio in Q2 2022 | History |
|---|---|---|---|---|---|
| TVTXTravere Therapeutics, Inc. | COM | 1,711,102 | $41.5M | 8.2% | History |
| VTGNVistagen Therapeutics, Inc. | COM NEW | 20,697,286 | $18.2M | 3.6% | History |
| WHWKWhitehawk Therapeutics, Inc. | COM | 1,173,518 | $14.5M | 2.8% | History |
| KDNYChinook Therapeutics, Inc. | COM | 489,618 | $8.56M | 1.7% | History |
| XENEXenon Pharmaceuticals Inc. | COM | 30,000 | $913.0K | 0.2% | History |